Last reviewed · How we verify
Ibuprofen and Aprepitant
This combination uses ibuprofen to reduce inflammation and pain via COX inhibition, while aprepitant blocks substance P receptors to prevent nausea and vomiting.
This combination uses ibuprofen to reduce inflammation and pain via COX inhibition, while aprepitant blocks substance P receptors to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) with concurrent pain management, Cancer-related pain with antiemetic support.
At a glance
| Generic name | Ibuprofen and Aprepitant |
|---|---|
| Also known as | NSAIDs, Neurokinin 1 Receptor antagonist |
| Sponsor | Lahore Medical Research Center, LLP |
| Drug class | NSAID + NK1 receptor antagonist combination |
| Target | COX-1/COX-2 (ibuprofen); NK1 receptor (aprepitant) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Pain Management |
| Phase | Phase 3 |
Mechanism of action
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Aprepitant is a neurokinin-1 (NK1) receptor antagonist that crosses the blood-brain barrier to block substance P signaling in the chemoreceptor trigger zone and vomiting center, providing antiemetic effects. The combination targets both pain/inflammation and chemotherapy-induced nausea and vomiting (CINV).
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) with concurrent pain management
- Cancer-related pain with antiemetic support
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Dizziness
- Constipation
- Upper abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibuprofen and Aprepitant CI brief — competitive landscape report
- Ibuprofen and Aprepitant updates RSS · CI watch RSS
- Lahore Medical Research Center, LLP portfolio CI